KẾT QUẢ ĐIỀU TRỊ U LYMPHO KHÔNG HODGKIN VÙNG RÌA BIỂU HIỆN TẠI HỐC MẮT

Abstract

Objective: To evaluate the initial treatment results of marginal zone lymphoma in the ocular adnexal area. Patients and Methods: Descriptive, case-cluster-study in 56 patients with newly diagnosed marginal zone lymphoma in the ocular adnexal area at Vietnam National Cancer Hosptial from March 2019 to June 2023. Results: The study was carried out on 56 patients. Median age was 39,5 ± 12,7; male:female ratio was 2,3:1. Palpable masses was the common presenting symptom (21,4%). A quarter of all patients had extraocular disease, primarily involving the lymph nodes (66,6%) and 87,5% patients were in stage I or II. The rate of stable disease after a 12-month observation treatment was 83,3%. For patients with treatment indications, the rate of complete reponse following treatment was 40,6%, with combination chemotherapy including Rituximab, it was 52,4%, Rituximab resulting in 50%, and radiation therapy showing 0%. The R-bendamustin regimen was the most frequently used and yielded the highest complete response rate at 60%. Conclusion: Observational management leads to a high level of effectiveness. The response rate among patients with treatment indications is positive, with combination chemotherapy  targeted treatment being the most effective, especially with the R-bendamustin regimen. Targeted therapy and radiation therapy are also viable treatment approaches for stage I.